Reko Biotech: Obtained Supplemental Drug Manufacturing License for Recombinant Herpes Zoster Vaccine

Reco Bio announced that its subsidiary has recently obtained the approval for an amendment to the "Drug Production License" issued by the Jiangsu Provincial Drug Administration, adding the production scope of recombinant herpes zoster vaccine and related adjuvant ingredients. This amendment marks a further expansion of the group's research and production capabilities in the field of preventive biological products, laying a solid foundation for subsequent drug market registration.